Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

Upstream Bio, Inc.NASDAQ: UPB

Total Assets · Q1 FY2026 · quarter ended Mar 2026

Total assets falls 30.3% from a year ago

Total assets stood at $318.05M at the end of Q1 FY2026, down 30.3% from a year earlier and down 10.1% from the prior quarter. Over 3 fiscal years it compounded at +167.5% a year.

Context

  • Total assets increased in 2 of the last 3 fiscal years.

What to watch

Whether total assets keeps falling in the next quarterly balance sheet after a -30.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$318.05M-10.1% QoQ
Last fiscal yearDec 2025
$353.77M-26.6% YoY
Year agoMar 2025
$456.17M-30.3% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.3%——
1 year-26.6%——
3-year CAGR+167.5%——
5-year CAGR——
10-year CAGR——

Total Assets history

USD · from the balance sheet

Latest · FY2025
353.77M USD
Year-over-year change
-26.6%
3-year CAGR
+167.5%

Total Assets vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -30.3% is the lowest of 10, against a peer median of +32.7%.
  • Over three fiscal years its annual growth of +167.5% compares with a peer median of +2.1%.
UPB Competitors
Total Assets for UPB and competitors
Company Period Latest balance YoY 3-year CAGR
SYRESpyre Therapeutics, Inc.Sep 2026$1.1B USD+117.9%+121.9%
NVAXNovavax, Inc.Mar 2026$1.04B USD-19.3%-19.5%
RLAYRelay Therapeutics, Inc.Jun 2026$967.46M USD+32.7%-17.3%
AMLXAmylyx Pharmaceuticals, Inc.Sep 2026$786.8M USD+116.9%-5.3%
NTLAIntellia Therapeutics, Inc.Mar 2026$758.78M USD-23.1%-17.9%
ZBIOZenas BioPharma, Inc.Mar 2026$747.68M USD+124.0%+72.6%
WVEWave Life Sciences Ltd.Mar 2026$583.54M USD+102.4%+63.4%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$472.67M USD-26.2%+2.1%
UPBUpstream Bio, Inc.Mar 2026$318.05M USD-30.3%+167.5%
PHVSPharvaris N.V.Sep 2026€295.06M EUR-12.9%+21.6%
Peer median (excluding UPB) —+32.7%+2.1%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents17.05M25.83M325.89M101.58M
Short-term Investments083.98M144.56M239.93M
Net Receivables412K236K1.18M668K
Inventory0000
Other Current Assets233K370K494K9.62M
Total Current Assets18.31M117M479.16M351.8M
Property, Plant & Equipment (Net)164K202K2.37M1.78M
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0000
Other Non-current Assets7K(1)194K194K
Total Non-current Assets171K202K2.56M1.98M
Total Assets18.48M117.2M481.72M353.77M
Account Payables712K1.99M4.04M2.73M
Short-term Debt000720K
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities893K2.17M2.7M10.01M
Total Current Liabilities4.86M6.52M10.74M13.45M
Long-term Debt000549K
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities119.77M233.81M00
Total Non-current Liabilities119.78M233.81M1.13M549K
Total Liabilities124.63M240.32M11.87M14M
Common Stock3K3K53K54K
Retained Earnings(107.44M)(127.97M)(190.78M)(334.22M)
Accumulated OCI021K(25K)530K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(106.16M)(123.13M)469.85M339.77M
Total Debt94K45K1.83M1.27M
Net Debt(16.96M)(25.79M)(324.06M)(100.31M)

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.